NCT07815665
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07815665
Title A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma (HARMONi-GU1)
Acronym HARMONi-GU1
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Summit Therapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Research Site NOT_YET_RECRUITING Phoenix Arizona 85054 United States Details
Research Site RECRUITING Los Angeles California 90067 United States Details
Research Site NOT_YET_RECRUITING Washington D.C. District of Columbia 20010 United States Details
Research Site NOT_YET_RECRUITING Jacksonville Florida 32224 United States Details
Research Site NOT_YET_RECRUITING Rochester Minnesota 55905 United States Details
Research Site NOT_YET_RECRUITING Nashville Tennessee 37203 United States Details
Research Site RECRUITING Spokane Washington 99208 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field